Bill Grambley, CEO of AllazoHealth, explains how his company attacks health inequalities by providing personalized pharmaceutical care with artificial intelligence (AI)-based platforms.
AI-based platforms can be utilized to predict patient behavior and personalize patient support experiences. AllazoHealth focuses on pharmaceutical manufacturers’ patient support and marketing programs to develop their AI platforms.
Grambley notes that rare disease patients face a unique set of challenges. These include proper diagnosis, access to experts, and navigating treatment options. Applying standard healthcare procedures or learnings to the rare disease population can also be difficult. Often, this is due to the individualized nature of rare disease symptoms and experiences and limited patient numbers.
To enhance the impact of patient support programs, Grambley emphasizes an individualized approach, treating each patient as a unique person. This involves leveraging AI and aggregating data to understand various characteristics and factors that describe each patient. This enables a tailored response to challenges such as barriers to starting or staying on therapy and interactions with the healthcare system.
Grambley also discusses the importance of personalized support by sharing the example of a friend, Ella, who has a rare disease. This example highlights how companies can fall short of providing the type of support each patient is looking for and how AI can help to bridge those gaps by offering proactive outreach and ongoing assistance.
To stay informed on rare disease updates, visit https://checkrare.com/